The following is a summary of “Causal relationship between major depressive disorder, anxiety disorder and constipation: a ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Harvard researchers have found that M. morganii may contribute to depression by producing an inflammatory molecule.

Speaking in depth about her depression, Welch shared the tell-tale signs that occur in her body when a depressive episode is ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

In 2019 an international team of researchers identified 109 genes that were associated in different combinations with eight different psychiatric disorders, including autism, ADHD, schizophrenia, ...

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

People with depression tend to prefer carbohydrate-rich foods, according to a new study published in Psychological Medicine. | Neuroscience ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Background: Major depressive disorder (MDD) is a chronic and highly disabling condition. Existing pharmacotherapies produce full remission in only 30% to 40% of treated patients. Antidepressants ...